Related Experiment Videos
Effect of MCI-186 on postischemic reperfusion injury in isolated rat heart
U Minhaz1, M Tanaka, H Tsukamoto
1First Department of Surgery, Tokai University School of Medicine, Kanagawa, Japan.
Abstract:
MCI-186 (3-methyl-1-phenyl-2-pyrazolin-5-one) is a newly developed antioxidant which has been shown to reduce brain edema in cerebral ischemia through inhibition of the lipoxygenase pathway of arachidonic acid. However, its effect on myocardial reperfusion injury after prolonged ischemia has not yet been demonstrated. We compared the mode of the effect of MIC-186 and recombinant human CuZn superoxide dismutase (rh-SOD) in isolated perfused rat hearts subjected to 60-min ischemia followed by 60-min reperfusion. Left ventricular developed pressure (LVDP), necrotic area and the release of creatine phosphokinase (CPK) and endogenous CuZn superoxide dismutase (endoge-SOD) were measured to evaluate myocardial damage. The decrease in left coronary flow (CBF) was measured as an index of the damage of left coronary circulation. MCI-186 (14.5 mg/L) was perfused for 10 min in the MCI group and rh-SOD (70 mg/L) was perfused during the reperfusion period in the SOD group starting 5 min prior to reperfusion. The release patterns of CPK and endoge-SOD were analyzed to elucidate the difference in the mode of protection of MCI-186 and rh-SOD. The LVDP remained higher in both MCI and SOD groups than that of control (76 +/- 1, 77 +/- 2 and 69 +/- 1% of preischemic value, respectively). The necrotic area was significantly attenuated in both MCI and SOD groups compared with that in the control group (16 +/- 1, 14 +/- 1 and 32 +/- 1%, respectively, p < 0.05). Total CPK release was lower in both MCI and SOD groups than in the control (78 +/- 7, 100 +/- 2 and 116 +/- 4 x 10(3) units/g myocardium respectively). The decrease in CPK release was more marked in the MCI group than that in the SOD group (p < 0.05). The reduction in CBF was significantly attenuated by the treatment with rh-SOD or MCI-186, but the effect was much higher in the SOD group than in the MCI group (69 +/- 5, 58 +/- 2, and 48 +/- 2% in SOD, MCI and control groups, respectively). The release pattern of endoge-SOD was identical to that of CPK and thus this did not distinguish the mode of effect of MCI-186 from that of rh-SOD. These results indicate that MCI-186 reduces reperfusion injury in isolated perfused hearts with prolonged ischemia and the effect is more closely related to the reduction of myocyte damage than the preservation of the coronary circulation.
Insights
MCI-186, an antioxidant, effectively reduces myocardial reperfusion injury in isolated rat hearts by minimizing myocyte damage, outperforming recombinant human CuZn superoxide dismutase in this aspect. This study highlights MCI-186
Area of Science:
- Cardiovascular Research
- Ischemia-Reperfusion Injury
- Antioxidant Therapy
Background:
- MCI-186 (3-methyl-1-phenyl-2-pyrazolin-5-one) is a novel antioxidant known to reduce cerebral edema.
- Its efficacy in mitigating myocardial reperfusion injury following prolonged ischemia remains undemonstrated.
- Recombinant human CuZn superoxide dismutase (rh-SOD) is a known agent for oxidative stress management.
Purpose of the Study:
- To compare the protective effects of MCI-186 and rh-SOD against myocardial reperfusion injury in isolated rat hearts.
- To elucidate the distinct mechanisms of action of MCI-186 and rh-SOD in preserving cardiac function and tissue integrity.
Main Methods:
- Isolated perfused rat hearts subjected to 60 minutes of ischemia followed by 60 minutes of reperfusion.
- Treatment groups included MCI-186, rh-SOD, and a control group.
- Assessment of myocardial damage included left ventricular developed pressure (LVDP), necrotic area, creatine phosphokinase (CPK) release, and coronary blood flow (CBF).
Main Results:
- Both MCI-186 and rh-SOD preserved LVDP and reduced necrotic area compared to control.
- MCI-186 demonstrated a more significant reduction in CPK release than rh-SOD, indicating less myocyte damage.
- rh-SOD provided superior preservation of coronary blood flow compared to MCI-186.
Conclusions:
- MCI-186 effectively mitigates myocardial reperfusion injury in prolonged ischemia models.
- The protective mechanism of MCI-186 is primarily linked to reducing myocyte damage rather than preserving coronary circulation.
- MCI-186 represents a promising therapeutic agent for managing cardiac ischemia-reperfusion injury.